Editorial
doi: 10.1002/hep.32319.
Epub 2022 Jan 22.
The rise and fall and rise again of ammonia as a therapeutic target in HE
Affiliations
- PMID: 34995377
- DOI: 10.1002/hep.32319
Item in Clipboard
Editorial
The rise and fall and rise again of ammonia as a therapeutic target in HE
Hepatology.
2022 May.
No abstract available
Comment on
-
L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.Hepatology. 2022 May;75(5):1194-1203. doi: 10.1002/hep.32255. Epub 2021 Dec 21. Hepatology. 2022. PMID: 34822189 Clinical Trial.
Similar articles
-
The role of astrocytes in hepatic encephalopathy.Neurochem Pathol. 1987 Feb-Apr;6(1-2):13-33. doi: 10.1007/BF02833599. Neurochem Pathol. 1987. PMID: 3306480 Review.
-
[The effects of Helicobacter pylori infection on hyperammonaemia and hepatic encephalopathy in cirrhotic patients].Zhonghua Nei Ke Za Zhi. 2006 Aug;45(8):654-7. Zhonghua Nei Ke Za Zhi. 2006. PMID: 17074151 Chinese.
-
Ammonia levels and the severity of hepatic encephalopathy.J Coll Physicians Surg Pak. 2014 Mar;24(3):160-3. J Coll Physicians Surg Pak. 2014. PMID: 24613109
-
The Role of Intestinal Bacteria and Gut-Brain Axis in Hepatic Encephalopathy.Front Cell Infect Microbiol. 2021 Jan 21;10:595759. doi: 10.3389/fcimb.2020.595759. eCollection 2020. Front Cell Infect Microbiol. 2021. PMID: 33553004 Free PMC article. Review.
-
[Helicobacter pylori and hepatic encephalopathy].Zhonghua Gan Zang Bing Za Zhi. 2018 Jul 20;26(7):553-556. doi: 10.3760/cma.j.issn.1007-3418.2018.07.016. Zhonghua Gan Zang Bing Za Zhi. 2018. PMID: 30317783 Review. Chinese.
Cited by
-
Development and validation of a machine learning-based model to predict survival in patients with cirrhosis after transjugular intrahepatic portosystemic shunt.EClinicalMedicine. 2024 Dec 16;79:103001. doi: 10.1016/j.eclinm.2024.103001. eCollection 2025 Jan. EClinicalMedicine. 2024. PMID: 39802305 Free PMC article.
-
The role of butyrylcholinesterase in the regulation of cognitive dysfunction in minimal hepatic encephalopathy: A potential blood marker of disease evolution.Front Neurol. 2022 Oct 20;13:900997. doi: 10.3389/fneur.2022.900997. eCollection 2022. Front Neurol. 2022. PMID: 36341087 Free PMC article.
References
-
- Tranah TH, Paolino A, Shawcross DL. Pathophysiological mechanisms of hepatic encephalopathy. Clin Liver Dis. 2015;5:59–63.
-
- Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, et al. Infection and systemic inflammation, not ammonia, are associated with grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol. 2011;54:640–9.
-
- Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open‐label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009;137:885–91.e1.
-
- Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–81.
-
- Patel VC, Lee S, McPhail MJW, Da Silva K, Guilly S, Zamalloa A, et al. Rifaximin‐alpha reduces gut‐derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. J Hepatol. 2021 Sep 24. https://doi.org/10.1016/j.jhep.2021.09.101 . [Epub ahead of print] - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
